Kyla N. Price
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kyla N. Price has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Vivian Yan Shi
Department of Dermatology University of Washington Seattle Washington USA
20 shared publications - Jennifer Lin Hsiao
Department of Dermatology University of Southern California Los Angeles California USA
15 shared publications Jennifer L. Hsiao
University of California, Los Angeles Los Angeles CA USA
5 shared publications- Jennifer M. Fernandez
Department of Dermatology, University of Nebraska Medical Center, Omaha, NE, USA
5 shared publications Afsaneh Alavi
Division of Dermatology, Women College Hospital, University of Toronto, Toronto, Ontario, Canada
4 shared publications- Swetha Atluri
University of Arizona College of Medicine Tucson AZ USA
4 shared publications
Latest Publications
- 19 March 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (10) , 2629-2632
National Institutes of Health Dermatology Funding Trends: 2020–2024
- 19 March 2025
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 145 (10) , 2629-2632
National Institutes of Health Dermatology Funding Trends: 2020–2024
- Open Access
- 8 August 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 860-862
Academic dermatology chair and chief characteristics
- 8 August 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (5) , 860-862
Open AccessAcademic dermatology chair and chief characteristics
- 1 August 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (8) , E323-E325
Topography of lesion progression in hidradenitis suppurativa
- 1 August 2021
- Published by Wiley in International Journal of Dermatology
- Vol. 60 (8) , E323-E325
Topography of lesion progression in hidradenitis suppurativa
- Open Access
- 1 June 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (3) , 346-348
Provider perspectives on the management of hidradenitis suppurativa in pregnancy – A survey study
- 1 June 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (3) , 346-348
Open AccessProvider perspectives on the management of hidradenitis suppurativa in pregnancy – A survey study
- Open Access
- 18 March 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (4) , 478-481
Art of prevention: Practical tips for improving adherence to treatments for older patients in dermatology
Given demographic changes and increases in longevity, physicians will see increasing numbers of patients over the age of 65 years. As the population ages, adapting and optimizing patient care to better serve the needs of older patients should be a priority. The goal of this review is to shed light on potential barriers affecting treatment adherence and to improve clinical care for older adults with dermatologic conditions. We provide practical strategies to help overcome these barriers and provide suggestions to address the impact of functional limitations on topical medication adherence. Some less apparent risks of treatment, such as fall risks with topical treatments, are also discussed, along with issues such as cost of treatments and prescribing considerations for patients who reside in facilities.
- 18 March 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (4) , 478-481
Open AccessArt of prevention: Practical tips for improving adherence to treatments for older patients in dermatology
Given demographic changes and increases in longevity, physicians will see increasing numbers of patients over the age of 65 years. As the population ages, adapting and optimizing patient care to better serve the needs of older patients should be a priority. The goal of this review is to shed light on potential barriers affecting treatment adherence and to improve clinical care for older adults with dermatologic conditions. We provide practical strategies to help overcome these barriers and provide suggestions to address the impact of functional limitations on topical medication adherence. Some less apparent risks of treatment, such as fall risks with topical treatments, are also discussed, along with issues such as cost of treatments and prescribing considerations for patients who reside in facilities.
- 20 February 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (2) , e14851
Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic and often debilitating inflammatory condition characterized by frequent nodules, abscesses, sinus tracts, and scars impacting the intertriginous areas. Many patients with HS often report limited treatment success and symptom coverage with conventional therapies. Recent studies have reported the widespread use of complementary and alternative medicine (CAM) among patients with HS. In this study, our aim was to examine current physician practice patterns, opinions, and comfort with recommending CAM. Our results indicate that provider comfort and opinions on CAM varied based on the provider's experiences, demographics, and the CAM modality itself. Overall, nearly two‐thirds (n = 30, 61.2%) of respondents agreed that CAM and conventional medicine were more effective together than either alone. Meanwhile, 44.9% (n = 22) of respondents routinely recommend CAM while 64.6% (n = 31) of respondents reported that they are routinely asked about CAM. The majority (n = 41, 83.7%) of respondents indicated a lack of scientific evidence in the medical literature as a barrier to recommending CAM along with efficacy concerns (n = 34, 69.4%) and ability to recommend reputable CAM products (n = 32, 65.3%) and practitioners (n = 32, 65.3%). Future investigations are warranted to establish a better understanding of the efficacy and benefit of CAM methods in conjunction with conventional methods.
- 20 February 2021
- Published by Wiley in Dermatologic Therapy
- Vol. 34 (2) , e14851
Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa
Hidradenitis suppurativa (HS) is a chronic and often debilitating inflammatory condition characterized by frequent nodules, abscesses, sinus tracts, and scars impacting the intertriginous areas. Many patients with HS often report limited treatment success and symptom coverage with conventional therapies. Recent studies have reported the widespread use of complementary and alternative medicine (CAM) among patients with HS. In this study, our aim was to examine current physician practice patterns, opinions, and comfort with recommending CAM. Our results indicate that provider comfort and opinions on CAM varied based on the provider's experiences, demographics, and the CAM modality itself. Overall, nearly two‐thirds (n = 30, 61.2%) of respondents agreed that CAM and conventional medicine were more effective together than either alone. Meanwhile, 44.9% (n = 22) of respondents routinely recommend CAM while 64.6% (n = 31) of respondents reported that they are routinely asked about CAM. The majority (n = 41, 83.7%) of respondents indicated a lack of scientific evidence in the medical literature as a barrier to recommending CAM along with efficacy concerns (n = 34, 69.4%) and ability to recommend reputable CAM products (n = 32, 65.3%) and practitioners (n = 32, 65.3%). Future investigations are warranted to establish a better understanding of the efficacy and benefit of CAM methods in conjunction with conventional methods.
- Open Access
- 5 February 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (4) , 441-444
Gender gaps in National Institutes of Health dermatology grant recipients
Understanding the demographics and scholarly merit among National Institutes of Health (NIH) award recipients can help guide future applicants in the field of dermatology. Herein, we aimed to explore gender gaps in NIH award recipient demographics and scholarly merits for dermatology-related projects. Projects funded by the National Institutes of Arthritis and Musculoskeletal and Skin Diseases between 2015 and 2019 related to dermatology were extracted using the NIH Research Portfolio Online Reporting Tools database. The number of publications and h-index of each award recipient were collected using the Scopus database. The 2019 Blue Ridge Institute for Medical Research report was used to determine the top 20 NIH-funded dermatology departments/divisions. Between 2015 and 2019, there were 35.1% more unique male than unique female recipients. Award recipients had an average of 116.7 total publications and an average h-index of 37.1. However, men also had more than half as many publications and a >37% higher average h-index. Gender gaps in research merit, as well as number and type of awards, are reduced among recipients affiliated with a top 20 NIH-funded institution. A higher number of awards were granted to male recipients. Men had a higher mean publication number and h-index compared with their female counterparts. Increased support, resources, and mentorship opportunities to women in research may help mitigate these gaps.
- 5 February 2021
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 7 (4) , 441-444
Open AccessGender gaps in National Institutes of Health dermatology grant recipients
Understanding the demographics and scholarly merit among National Institutes of Health (NIH) award recipients can help guide future applicants in the field of dermatology. Herein, we aimed to explore gender gaps in NIH award recipient demographics and scholarly merits for dermatology-related projects. Projects funded by the National Institutes of Arthritis and Musculoskeletal and Skin Diseases between 2015 and 2019 related to dermatology were extracted using the NIH Research Portfolio Online Reporting Tools database. The number of publications and h-index of each award recipient were collected using the Scopus database. The 2019 Blue Ridge Institute for Medical Research report was used to determine the top 20 NIH-funded dermatology departments/divisions. Between 2015 and 2019, there were 35.1% more unique male than unique female recipients. Award recipients had an average of 116.7 total publications and an average h-index of 37.1. However, men also had more than half as many publications and a >37% higher average h-index. Gender gaps in research merit, as well as number and type of awards, are reduced among recipients affiliated with a top 20 NIH-funded institution. A higher number of awards were granted to male recipients. Men had a higher mean publication number and h-index compared with their female counterparts. Increased support, resources, and mentorship opportunities to women in research may help mitigate these gaps.
- 1 January 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (1) , 232-235
National Institutes of Health Dermatology Funding Trends 2015–2019
- 1 January 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (1) , 232-235
National Institutes of Health Dermatology Funding Trends 2015–2019
- 15 December 2020
- Published by S. Karger AG in Dermatology
- Vol. 237 (5) , 843-846
Facilitating Clinical Trials Participation of Low Socioeconomic Status Patients
Socioeconomic status represents social standing measured by the combination of education, income, and occupation [1]. Financial barriers and lack of education generate a number of obstacles to receiving adequate healthcare and treatment. A recent study exploring demographics of cancer clinical trial participants found that patients with an annual household income of less than USD 50,000 had 32% lower odds of trial participation than patients with above USD 50,000 [2]. There is limited data reporting low socioeconomic status (LSES) and participation in dermatology clinical trials; however, it is not unlikely that financial barriers result in similar disparities. These findings support the need to represent and care for LSES groups in clinical trials.
- 15 December 2020
- Published by S. Karger AG in Dermatology
- Vol. 237 (5) , 843-846
Facilitating Clinical Trials Participation of Low Socioeconomic Status Patients
Socioeconomic status represents social standing measured by the combination of education, income, and occupation [1]. Financial barriers and lack of education generate a number of obstacles to receiving adequate healthcare and treatment. A recent study exploring demographics of cancer clinical trial participants found that patients with an annual household income of less than USD 50,000 had 32% lower odds of trial participation than patients with above USD 50,000 [2]. There is limited data reporting low socioeconomic status (LSES) and participation in dermatology clinical trials; however, it is not unlikely that financial barriers result in similar disparities. These findings support the need to represent and care for LSES groups in clinical trials.
- Open Access
- 1 December 2020
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 6 (5) , 372-376
Characterizing perimenstrual flares of hidradenitis suppurativa
Hidradenitis suppurativa (HS) predominantly affects women of childbearing age, and sex hormones are thought to play a role in HS pathogenesis. However, there is a paucity of data regarding the pattern of HS perimenstrual flares, as well as patient responses to hormone-based therapies. We aimed to characterize the temporal pattern of perimenstrual flares, as well as factors associated with perimenstrual flares. We also sought to investigate responses to hormonal therapies in women with HS. An anonymous web-based questionnaire was distributed to various online HS support groups in May 2020. A total of 283 participants met the inclusion criteria as adult women who self-reported having HS and menstrual cycles. The majority (176 of 282 women; 62.4%) reported HS worsening with menses, and 86.9% (153 of 176 women) noted that perimenstrual HS flares occurred always or often. Most women (138 of 175 women; 78.9%) reported that their HS flared in the week preceding menses. Perimenstrual HS flares were more likely in women with a family history of HS compared with those without (49.6% vs. 28.2%; p = .019). More than a third of respondents who had been treated with spironolactone reported improvement of HS symptoms, but more than a quarter of participants who used medroxyprogesterone acetate or used a hormonal intrauterine device reported worsened HS symptoms. Female patients with HS have high rates of perimenstrual HS flares, specifically during the week preceding the onset of menses. Additional investigations on the role of sex hormones in HS pathogenesis and the efficacy of hormone-based therapies are warranted.
- 1 December 2020
- Published by Wolters Kluwer Health in International Journal of Women's Dermatology
- Vol. 6 (5) , 372-376
Open AccessCharacterizing perimenstrual flares of hidradenitis suppurativa
Hidradenitis suppurativa (HS) predominantly affects women of childbearing age, and sex hormones are thought to play a role in HS pathogenesis. However, there is a paucity of data regarding the pattern of HS perimenstrual flares, as well as patient responses to hormone-based therapies. We aimed to characterize the temporal pattern of perimenstrual flares, as well as factors associated with perimenstrual flares. We also sought to investigate responses to hormonal therapies in women with HS. An anonymous web-based questionnaire was distributed to various online HS support groups in May 2020. A total of 283 participants met the inclusion criteria as adult women who self-reported having HS and menstrual cycles. The majority (176 of 282 women; 62.4%) reported HS worsening with menses, and 86.9% (153 of 176 women) noted that perimenstrual HS flares occurred always or often. Most women (138 of 175 women; 78.9%) reported that their HS flared in the week preceding menses. Perimenstrual HS flares were more likely in women with a family history of HS compared with those without (49.6% vs. 28.2%; p = .019). More than a third of respondents who had been treated with spironolactone reported improvement of HS symptoms, but more than a quarter of participants who used medroxyprogesterone acetate or used a hormonal intrauterine device reported worsened HS symptoms. Female patients with HS have high rates of perimenstrual HS flares, specifically during the week preceding the onset of menses. Additional investigations on the role of sex hormones in HS pathogenesis and the efficacy of hormone-based therapies are warranted.